<antigenSupportingData>
<immunity>
</immunity>
<contraindications>
<vaccineGroup>
<contraindication>
<observationCode>080</observationCode>
<observationTitle>Adverse reaction to vaccine component</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had an adverse reaction to a vaccine component.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>145</observationCode>
<observationTitle>B-lymphocyte [humoral] - Severe antibody deficiencies</observationTitle>
<contraindicationText>Do not vaccinate if the patient has severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>146</observationCode>
<observationTitle>B-lymphocyte [humoral] - Less severe antibody deficiencies</observationTitle>
<contraindicationText>Do not vaccinate if the patient has less severe B-lymphocyte (humoral) - antibody deficiencies (e.g., selective IgA deficiency and IgG subclass deficiency).</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>147</observationCode>
<observationTitle>T-lymphocyte [cell-mediated and humoral] - Complete defects</observationTitle>
<contraindicationText>Do not vaccinate if the patient has complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>148</observationCode>
<observationTitle>T-lymphocyte [cell-mediated and humoral] - Partial defects</observationTitle>
<contraindicationText>Do not vaccinate if the patient has partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>150</observationCode>
<observationTitle>T-lymphocyte [cell-mediated and humoral] - interferon-gamma or interferon-alpha</observationTitle>
<contraindicationText>Do not vaccinate if the patient has cell-mediated or humoral T-lymphocyte defects related to interferon-gamma or interferon-alpha</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>153</observationCode>
<observationTitle>Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency</observationTitle>
<contraindicationText>Do not vaccinate if the patient has a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>154</observationCode>
<observationTitle>HIV/AIDS - severely immunocompromised</observationTitle>
<contraindicationText>Do not vaccinate if the patient has HIV/AIDS and is severely immunocompromised (See the CDC general recommendations for a definition of "severely immunocompromised").</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>156</observationCode>
<observationTitle>Generalized malignant neoplasm</observationTitle>
<contraindicationText>Do not vaccinate if the patient has generalized malignant neoplasm.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>157</observationCode>
<observationTitle>Sold organ transplantation</observationTitle>
<contraindicationText>Do not vaccinate if the patient received a solid organ transplant.</contraindicationText>
<contraindicationGuidance>Certain immunosuppressive medications are administered to prevent solid organ transplant rejection. Live vaccines should be withheld for 2 months following discontinuation of anti-rejection therapies in patients with a solid organ transplant.</contraindicationGuidance>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>158</observationCode>
<observationTitle>Immunosuppressive therapy</observationTitle>
<contraindicationText>Do not vaccinate if the patient is undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. </contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>159</observationCode>
<observationTitle>Radiation therapy</observationTitle>
<contraindicationText>Do not vaccinate if the patient is undergoing radiation therapy.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>210</observationCode>
<observationTitle>Severe allergic reaction after previous dose of Dengue vaccine</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of Dengue vaccine.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>243</observationCode>
<observationTitle>Lack of laboratory confirmation of a previous Dengue infection</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of Dengue vaccine.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
</vaccineGroup>
</contraindications>
<series>
<seriesName>Dengue risk 3-dose series</seriesName>
<targetDisease>Dengue</targetDisease>
<vaccineGroup>Dengue</vaccineGroup>
<seriesAdminGuidance>Administer to persons with evidence of previous dengue infection and living in areas where dengue is endemic. Evidence of previous dengue infection, such as confirmation with previous laboratory-confirmed infection or a highly specific serodiagnostic test, will be required among eligible children before vaccination.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>Yes</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>1</seriesPreference>
<minAgeToStart/>
<maxAgeToStart>17 years</maxAgeToStart>
</selectSeries>
<indication>
<observationCode>
<text>Evidence of previous dengue infection and living in areas where dengue is endemic</text>
<code>211</code>
</observationCode>
<description>Administer to persons with evidence of previous dengue infection and living in areas where dengue is endemic.</description>
<beginAge>9 years</beginAge>
<endAge>17 years</endAge>
<guidance>Evidence of previous dengue infection, such as confirmation with previous laboratory-confirmed infection or a highly specific serodiagnostic test, will be required among eligible children before vaccination.</guidance>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>9 years - 4 days</absMinAge>
<minAge>9 years</minAge>
<earliestRecAge>9 years</earliestRecAge>
<latestRecAge/>
<maxAge>17 years</maxAge>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine>
<vaccineType>Dengue Fever</vaccineType>
<cvx>56</cvx>
<beginAge>9 years</beginAge>
<endAge>17 years</endAge>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>Dengue Fever</vaccineType>
<cvx>56</cvx>
<beginAge>9 years - 4 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge/>
<minAge/>
<earliestRecAge/>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>Dengue Fever</vaccineType>
<cvx>56</cvx>
<beginAge>9 years</beginAge>
<endAge>17 years</endAge>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>Dengue Fever</vaccineType>
<cvx>56</cvx>
<beginAge>9 years - 4 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge/>
<minAge/>
<earliestRecAge/>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>Dengue Fever</vaccineType>
<cvx>56</cvx>
<beginAge>9 years</beginAge>
<endAge>17 years</endAge>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>Dengue Fever</vaccineType>
<cvx>56</cvx>
<beginAge>9 years - 4 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
</antigenSupportingData>
